Known so far: no new shares from the prospectus covers read · shelf room about $21.5M · not yet read: warrants, converts, options, ATM.
Shelf room
Room todayabout $21.5M, maybe lower
One third of float$21.5M ($64.4M float, Jun 30, 2025)
Sold off it, 12 monthsnothing
How this is worked out
Shelf room about $21.5M on the S-3 of Aug 20, 2026: the baby-shelf rule (public float under $75M) caps sales at one third of the $64.4M public float stated as of Jun 30, 2025, $21.5M, nothing sold off it in the last 12 months; 1 more sale off the shelf with no size read, so the room may be lower. Sources: S-3 Aug 20, 2026, effective Aug 27, 2026 · public float, as of Jun 30, 2025 · 424B2 Aug 28, 2026.
What could become new Pyxis Oncology (PYXS) shares, from its 10-Q, 10-K, S-3 or 424B filings.
Read so far: the cover share count (83.4M shares, +34% from 62.0M on Aug 13, 2025). Not read yet: warrants, convertible notes, options and RSUs and an ATM program.Read them on EDGAR: the latest 10-Q · S-3 shelf filings.
Registrations and share actions on EDGAR (36 filings)
Registration statements, prospectuses, effectiveness notices, information statements and share sales, newest first. Showing the newest 15 of 36. Each links to the filing on EDGAR.
8-K + 424B5Financing: agreement (8-K) with a 424B5 prospectus filed the same daySize not read yet
424B5Prospectus for shares being soldSize not read yet
424B5Prospectus for shares being soldSize not read yet
424B2Prospectus for shares being soldSize not read yet